TSE:4536Pharmaceuticals
Santen Pharmaceutical (TSE:4536): Assessing Valuation After UK Approval of Ryjunea for Pediatric Myopia
Santen Pharmaceutical (TSE:4536) just received approval from the UK medicines regulator for its new pediatric myopia treatment, Ryjunea. This move strengthens the company’s footprint in Europe and signals a growing opportunity in children’s eye health.
See our latest analysis for Santen Pharmaceutical.
Santen Pharmaceutical’s shares have shown fresh momentum lately, helped by regulatory wins and a sizable buyback program that wrapped up just last week. While the stock’s year-to-date price...